Trump prescription plan doesn’t include Medicare-negotiated pricing
Published by McKnight’s LTC News
President Donald Trump’s “blueprint” for lowering prescription costs goes after pharmacy benefit managers but stops short of recommending Medicare-negotiated prices, a plank he campaigned on in 2016.
Though Trump on Friday afternoon called for eliminating the middlemen who “became very, very rich” negotiating prices for insurers and large employers, the 45-page plan offers no specifics as to how he’ll limit the role they play.
PBMs have come under increasing scrutiny since the president’s economic advisory council issued a February report that highlighted their dominance in senior healthcare settings.
Some critics said Trump’s new focus on PBMs allows drug makers to slip off his radar, and industry stocks rose after the speech — a sign that pharmaceutical investors didn’t feel threatened by Trump’s plan.
The Senior Care Pharmacy Coalition has long called for stricter controls. In a statement made just before Trump’s speech, the group lauded the administration’s “objective assessments of a drug pricing marketplace and regulatory framework failing consumers and failing our nation.”
Coalition President and CEO Alan G. Rosenbloom expressed concern about a dramatic round of mergers and acquisitions among insurance companies, PBMs, distributors, providers and others resulting in “worrisome consolidation.”
Other seniors advocates called the blueprint a good first step, though some had hoped the president would empower the government to play a larger role in price setting.
“AARP has long supported … allowing the Secretary of Health and Human Services to negotiate lower drug prices on behalf of millions of Medicare beneficiaries,” Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond said in a statement.
AARP leaders said they also hoped to see Trump address drug imports, reduce exclusivity for high-priced biologic drugs, prohibiting pay-for-delay deals between brand and generic drug companies, and demand greater transparency.
The blueprint, which raised a series of questions about the drug-pricing chain and touted Trump’s previous budget initiatives aimed at Medicare Part D reform, moved away from many of the specific proposals he touted while campaigning.
The president does want stricter policing of delay tactics, to make advertisements more transparent about pricing, and to stifle gag clauses that prevent some consumers from learning about rebates and lower-priced drug alternatives.
“The drug lobby is making an absolute fortune at the expense of American consumers,” Trump said. “We are putting American patients first.”
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.